Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En fase 2b klinisk studie av YN001 hos voksne med koronar aterosklerose (PURIFY-TIMI 81)

3. november 2026 oppdatert av: Beijing Inno Medicine Co., Ltd.

En randomisert, multiklinisk, dobbeltblind, parallell, placebokontrollert fase 2b klinisk studie for å evaluere effekt og sikkerhet av YN001 hos voksne med koronar aterosklerose

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

Studieoversikt

Detaljert beskrivelse

This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.

A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).

Studietype

Intervensjonell

Registrering (Antatt)

456

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • New South Wales
      • Penrith, New South Wales, Australia, 2750
        • Rekruttering
        • Cannopy Clinical Research
        • Ta kontakt med:
    • Queensland
      • Brisbane, Queensland, Australia, 4064
        • Rekruttering
        • Core Research Group Pty Ltd.
        • Ta kontakt med:
    • Victoria
      • Altona N., Victoria, Australia, 3025
        • Rekruttering
        • Canopy Clinical Research
        • Ta kontakt med:
    • Manitoba
      • Winnipeg, Manitoba, Canada, R2H 2A6
        • Har ikke rekruttert ennå
        • St. Boniface Hospital
        • Ta kontakt med:
    • Ontario
      • London, Ontario, Canada, N5A 5A5
        • Har ikke rekruttert ennå
        • London Health Sciences Centre
        • Ta kontakt med:
      • North York, Ontario, Canada, M6B 3H7
        • Har ikke rekruttert ennå
        • North York Diagnostic and Cardiac Centre
        • Ta kontakt med:
      • Toronto, Ontario, Canada, M5B 1W8
        • Har ikke rekruttert ennå
        • St. Michael's Hospital
        • Ta kontakt med:
      • Vaughan, Ontario, Canada, L6A 4N9
        • Har ikke rekruttert ennå
        • Cardiac Clinic
        • Ta kontakt med:
    • Toronto
      • Toronto, Toronto, Canada, M5G 2N2
        • Har ikke rekruttert ennå
        • Toronto General Hospital - University Health Network
        • Ta kontakt med:
    • Alabama
      • Huntsville, Alabama, Forente stater, 35801-4312
        • Rekruttering
        • Heart Center Research, LLC
        • Ta kontakt med:
    • California
      • Covina, California, Forente stater, 91740
      • Lincoln, California, Forente stater, 95648
        • Har ikke rekruttert ennå
        • Clinical Trials Research
        • Ta kontakt med:
      • Los Alamitos, California, Forente stater, 90720
        • Har ikke rekruttert ennå
        • University of California Irvine Medical Center - Cardiovascular Center
        • Ta kontakt med:
      • Stanford, California, Forente stater, 94305-2200
        • Har ikke rekruttert ennå
        • Stanford Health Care General Cardiology
        • Ta kontakt med:
      • Torrance, California, Forente stater, 90502-2006
        • Rekruttering
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
        • Ta kontakt med:
    • Florida
      • Boca Raton, Florida, Forente stater, 33434
        • Har ikke rekruttert ennå
        • Flourish Research - Boca Raton
        • Ta kontakt med:
      • Hialeah, Florida, Forente stater, 33016-1895
        • Rekruttering
        • New Generation of Medical Research, LLC.
        • Ta kontakt med:
      • St. Petersburg, Florida, Forente stater, 33709
    • Georgia
      • Atlanta, Georgia, Forente stater, 30303-3049
        • Har ikke rekruttert ennå
        • Emory Healthcare-Emory Heart & Vascular Center - Executive Park
        • Ta kontakt med:
    • Idaho
      • Meridian, Idaho, Forente stater, 83642
        • Har ikke rekruttert ennå
        • St. Luke's Clinic - Idaho Cardiology Associates
        • Ta kontakt med:
    • Illinois
      • Springfield, Illinois, Forente stater, 62781
        • Har ikke rekruttert ennå
        • Southern Illinois University School of Medicine
        • Ta kontakt med:
    • Kansas
      • Overland Park, Kansas, Forente stater, 66211-1215
        • Rekruttering
        • Midwest Heart & Vascular Specialists, LLC
        • Ta kontakt med:
    • Missouri
      • St Louis, Missouri, Forente stater, 63110-1032
        • Rekruttering
        • WU School of Medicine - (CAM) - Heart and Vascular Center
        • Ta kontakt med:
    • North Carolina
      • Raleigh, North Carolina, Forente stater, 27607
        • Har ikke rekruttert ennå
        • NC Heart and Vascular Research, LLC
        • Ta kontakt med:
      • Winston-Salem, North Carolina, Forente stater, 27104-3520
        • Har ikke rekruttert ennå
        • Javara Inc. - Wake Forest University Health Sciences
        • Ta kontakt med:
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73135
        • Har ikke rekruttert ennå
        • South Oklahoma Heart Research, LLC
        • Ta kontakt med:
    • Pennsylvania
      • Camp Hill, Pennsylvania, Forente stater, 17011
        • Rekruttering
        • Capital Area Research, LLC - Camp Hill
        • Ta kontakt med:
    • Texas
      • Amarillo, Texas, Forente stater, 79106
        • Rekruttering
        • PharmaTex Research, LLC
        • Ta kontakt med:
      • Carrollton, Texas, Forente stater, 75010
        • Har ikke rekruttert ennå
        • Pulse Care Heart and Vascular
        • Ta kontakt med:
      • Tomball, Texas, Forente stater, 77375
        • Har ikke rekruttert ennå
        • DM Clinical Research - Dallas
        • Ta kontakt med:
    • An
      • Hefei, An, Kina, 230022
        • Rekruttering
        • The First Affiliated Hospital of Anhui Medical Unversity
        • Ta kontakt med:
          • Jianlong Wang, MD
          • Telefonnummer: 0086-13681292304
          • E-post: Wjlmll@sina.com
    • Anhui
      • Hefei, Anhui, Kina, 230001
        • Rekruttering
        • Anhui Provincial Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kangyu Chen, MD
        • Underetterforsker:
          • Chao Gao, MD
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100035
        • Rekruttering
        • Beijing Jishuitan Hospital
        • Hovedetterforsker:
          • Wei Liu, MD
        • Ta kontakt med:
          • Qingwei Ji, MD
          • Telefonnummer: 0086 18376642655
          • E-post: jqwl24@163.cou
        • Hovedetterforsker:
          • Qingwei Ji, MD
      • Beijing, Beijing Municipality, Kina, 100029
        • Rekruttering
        • Anzhen Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yuyang Liu, MD
      • Beijing, Beijing Municipality, Kina, 101100
        • Har ikke rekruttert ennå
        • Beijing Luhe Hospital
        • Ta kontakt med:
    • Fujian
      • Fuzhou, Fujian, Kina, 350001
        • Rekruttering
        • Fujian Medical University Union Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mingfang Ye, MD
        • Underetterforsker:
          • Zhaoyang Chen, MD
    • Gansu
      • Lanzhou, Gansu, Kina, 730030
        • Rekruttering
        • The Second Hospital & Clinical Medical School Lanzhou University
        • Ta kontakt med:
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
        • Rekruttering
        • Guangdong Provincial People's Hospital
        • Ta kontakt med:
        • Ta kontakt med:
    • Heilongjiang
      • Daqing, Heilongjiang, Kina, 163316
        • Rekruttering
        • Daqing People's Hospital
        • Ta kontakt med:
      • Harbin, Heilongjiang, Kina, 150001
        • Rekruttering
        • The First Affiliated Hospital of Harbin Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lu Fu, MD
        • Hovedetterforsker:
          • Yongtai Gong, MD
    • Hubei
      • Wuhan, Hubei, Kina, 430071
        • Rekruttering
        • Zhongnan Hospital of Wuhan University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xiaorong Hu, MD
    • Hunan
      • Changsha, Hunan, Kina, 410008
        • Rekruttering
        • The Second Xiangya Hospital fo Central South University
        • Ta kontakt med:
    • Jilin
      • Changchun, Jilin, Kina, 130033
        • Rekruttering
        • The First Hospital of Jilin University
        • Hovedetterforsker:
          • Qian Tong, MD
        • Ta kontakt med:
    • Liaoning
      • Shenyang, Liaoning, Kina, 110015
        • Rekruttering
        • The People's Hospital of Liaoning Province
        • Hovedetterforsker:
          • Ying Liu, MD
        • Ta kontakt med:
    • Shaanxi
      • Xi'an, Shaanxi, Kina, 710068
        • Rekruttering
        • Shaanxi Provincial People's Hospital
        • Ta kontakt med:
    • Shandong
      • Jinan, Shandong, Kina
        • Rekruttering
        • Central Hospital Affiliated to Shandong First Medicial University
        • Ta kontakt med:
          • Guohai Su, MD
          • Telefonnummer: 0086 19953193319
          • E-post: gttstg@163.com
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200032
        • Rekruttering
        • Fudan University-Zhongshan Hospital
        • Hovedetterforsker:
          • Junbo Ge, MD
        • Ta kontakt med:
        • Underetterforsker:
          • Yuxiang Dai, MD
      • Shanghai, Shanghai Municipality, Kina, 200001
        • Rekruttering
        • Renji Hospital Shanghai Jiaotong University school of medicine
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jun Bu, MD
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Rekruttering
        • West China Hospital of Sichuan University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yong He, MD
      • Chengdu, Sichuan, Kina, 610072
        • Rekruttering
        • Sichuan Provincial People's Hospital
        • Ta kontakt med:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300211
        • Rekruttering
        • The Second Hospital of Tianjin Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tong Liu, MD
      • Tianjin, Tianjin Municipality, Kina, 300121
        • Rekruttering
        • Tianjin People's Hospital
        • Hovedetterforsker:
          • Zhuhua Yao, MD
        • Ta kontakt med:
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310006
        • Rekruttering
        • Zhejiang Provincial People's Hospital
        • Ta kontakt med:
      • Suzhou, Zhejiang, Kina, 215006
        • Rekruttering
        • The First Affiliated Hospital of Soochow University
        • Ta kontakt med:
      • Wenzhou, Zhejiang, Kina, 325000
        • Rekruttering
        • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
  2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
  3. Participants must satisfy either of the following criteria:

1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:

  1. A history of Type 2 diabetes requiring treatment with medication,

  2. Aged > 55 years (women) or > 50 years (men),

  3. 2 or more of the following atherosclerosis risk factors:

    • Current cigarette smoker

    • Hypertension

    • Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2

      4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.

      5. Female participants must be non-pregnant and non-lactating

      6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.

Exclusion Criteria:

  1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
  4. Contraindication for CCTA
  5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
  6. Acute MI that occurred within 4 weeks prior to randomization.
  7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
  8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
  9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
  10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
  11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
  12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
  13. History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
  14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
  15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
  16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
  17. Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  18. Presence of any type of autoimmune disease.
  19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
  20. Life expectancy is less than 1 year.
  21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
  22. Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
  23. LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
  24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
  25. Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
  26. Untreated or inadequately treated hypothyroidism.
  27. Poorly controlled Type 2 diabetes mellitus.
  28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Dose 1 YN001/Placebo 40mg

Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly

Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Eksperimentell: Dose 2 YN001/Placebo 20mg

Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly

YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Placebo komparator: Dose 3 YN001/Placebo 0mg

Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly

YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Relative change from baseline in coronary NCPV at Week 13
Tidsramme: Baseline to Week 13

Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA)

Baseline to Week 13

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Tidsramme: From baseline to Week 13

Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound.

From baseline to Week 13
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Tidsramme: From baseline to Week 9

Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9

From baseline to Week 9
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Tidsramme: From baseline to Week 13

Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound

From baseline to Week 13
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Tidsramme: From baseline to Week 9 and Week 13

Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound

From baseline to Week 9 and Week 13
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Tidsramme: From baseline to Week 13

Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA

From baseline to Week 13
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Tidsramme: From baseline to week 13

Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA.

From baseline to week 13
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Tidsramme: From baseline to week 48

Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA

From baseline to week 48
Absolute change in coronary NCPV at week 13 and week 48
Tidsramme: From baseline to week 13 and week 48

Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA

From baseline to week 13 and week 48
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Tidsramme: From randomization to Week 96

Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina

From randomization to Week 96
The safety profile of YN001
Tidsramme: From baseline to Week 13

Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI)

From baseline to Week 13
Immunogenicity (ADA) analysis
Tidsramme: From baseline to Week 13

Incidence of anti-drug antibodies (ADA) formation

From baseline to Week 13
Immunogenicity (APA) analysis
Tidsramme: From baseline to Week 17

Incidence of anti-PEG antibodies (APA) formation

From baseline to Week 17
YN001 concentrations analysis in plasma
Tidsramme: From baseline to Week 13

Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models

From baseline to Week 13

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

31. juli 2026

Primær fullføring (Antatt)

31. juli 2027

Studiet fullført (Antatt)

31. mars 2029

Datoer for studieregistrering

Først innsendt

2. april 2026

Først innsendt som oppfylte QC-kriteriene

2. april 2026

Først lagt ut (Faktiske)

9. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • YN001-203
  • IND 157167 (Registeridentifikator: Beijing Inno Medicine Co., Ltd.)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere